Lead Gene Therapy Program
Chronic Hepatitis B Virus (HBV) Infection
Pre-clinicalActive
Key Facts
About HBVtech
HBVtech is a private, preclinical-stage biotech company founded in 2016 and headquartered in Rockville, MD. The company's core asset is a proprietary gene therapy platform aimed at delivering lasting cures for chronic infections via a single injection, with its lead candidate targeting chronic hepatitis B. Operating as a pre-revenue therapeutics developer, HBVtech is positioned in a high-need market with significant unmet medical need, though it faces the technical and financial risks inherent to early-stage gene therapy development. Its success hinges on advancing its platform from preclinical research into clinical trials.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B Virus (HBV) Infection Drugs
| Drug | Company | Phase |
|---|---|---|
| IMC-M113V (HBV ImmTAV) | Immunocore | Phase 1 |
| PBGENE-HBV | Precision BioSciences | Phase 1/2 |